Navigation Links
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy

MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC. (NASDAQ: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a randomized, double-blind, multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofol disodium) Injection for sedation of patients undergoing bronchoscopy successfully met its primary endpoint of sedation success as well as all secondary endpoints. Among patients who received an initial bolus dose of 6.5 mg/kg of Aquavan, the sedation success rate was 88.7% compared to 27.5% of patients in the control arm (p less than 0.001). Results of this trial also indicate that the safety profile of the 6.5 mg/kg dose of Aquavan was predictable and similar to the safety profile of the control.

Data from the phase 3 bronchoscopy trial, together with the results from a phase 3 trial in patients undergoing colonoscopy and an open-label study in patients undergoing minor surgical procedures, will form the foundation of the Aquavan New Drug Application (NDA). MGI PHARMA plans to submit the Aquavan NDA to the U.S. Food and Drug Administration (FDA) early in the third quarter of 2007. As is consistent with standard medical practice, the three trials comprising the Aquavan pivotal program were conducted without monitored anesthesia care (MAC) sedation, and study drugs were administered by medical personnel as dictated by local investigative site guidelines.

"With more than 40 million procedures per year in the U.S. requiring moderate sedation, Aquavan may address a significant market opportunity," said Lonnie Moulder, President and Chief Executive Officer of MGI PHARMA. "The results of this pivotal program, together with completed pharmacokinetic studies, indicate that Aquavan has a pharmacokinetic and pharmacodynamic profile which may facilitate achievement and maintenance of targeted, controlled sedation by proceduralists. This unique profile may allow pati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:5/4/2015)... May 4, 2015   Synthetic Biologics, Inc. ... on protecting the microbiome, as well as treating other ... appointed Chief Financial Officer, Treasurer and Secretary effective June ... who will be leaving the Company in May to ... Synthetic Biologics operational, financial and international biotech industry experience, ...
(Date:5/4/2015)... BOULDER, Colo., May 4, 2015  Array BioPharma ... for the third quarter of its fiscal year ... Chief Executive Officer of Array, noted, "With the close ... binimetinib and encorafenib, two innovative oncology products in ... each product in 2016. These transformative transactions have ...
(Date:5/4/2015)... , May 4, 2015 ... has granted an Orphan Drug Designation (ODD) for rimeporide, ... dystrophy (DMD). DMD is a rare, life-threatening disease affecting ... muscle loss. It is the most common and serious ... a selective sodium/proton exchanger type-1 inhibitor, originally developed by ...
Breaking Medicine Technology:Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Peacock Alley ... our mothers. He said, “My mother was the most beautiful ... wrap her in lovely, feminine prints and textures ... Look no further than the Eloise Robe to get you ... with its cap sleeve and tapered waist. It is available ...
(Date:5/4/2015)... Today, Cireson reveals the following key ... to strengthen core service & asset management solutions ... consume Microsoft System Center and Cireson via Microsoft Azure ... Company transitioning from a direct sales presence to ... with expanding new solutions for password reset management, gamification, ...
(Date:5/3/2015)... Singapore (PRWEB) May 03, 2015 ... enterprise collaboration across platforms and devices, today announced ... Association of Privacy Professionals (IAPP) Asia Privacy Forum, ... Hotel Orchard. Throughout the event, AvePoint will showcase ... hybrid, and cloud platforms. , Visit AvePoint for ...
(Date:5/3/2015)... Michigan (PRWEB) May 03, 2015 ... on their Facebook page. , Their Facebook ... the many services the Practice has, it’s multiple locations, ... , Women’s Excellence has a very strong social media ... Instagram and You Tube. , Women’s Excellence is ...
(Date:5/3/2015)... 2015 Leading international program provider, ... be awarding the 2015 Harris Wofford Global Service Fellowships. ... are the deserving recipients of the award named after ... Llewellyn Wofford. The two recipients were chosen for their ... health. , CFHI is one of seven organizations ...
Breaking Medicine News(10 mins):Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3
... LOS ANGELES, Sept. 1 Azteca America television network is proud ... Gavin Newsom on the Sept. 1 broadcast of "Issues: Caras ... , , As a self-styled "social liberal and ... healthcare and San Francisco is probably the highest profile city in ...
... 21 hours later with milder heart attacks, study shows , ... at hospital emergency rooms with chest pains can wait as ... electrocardiogram (EKG) shows evidence of a heart attack, a new ... key measures of heart damage and one-month death rates in ...
... , , National Veterans ... WASHINGTON, Sept. 1 More than 120 Veterans from across ... writing or visual arts contests are preparing to attend the National Veterans ... , "The Creative Arts Festival represents the top achievements ...
... ... orthopaedic surgeons Dr. James R. Andrews and Dr. Lonnie Paulos now beginning its second ... Gulf ... Sports Medicine is now providing free orthopaedic exams and assessments to high school ...
... , , , ... American Imaging Management(R) (AIM), an operating subsidiary of WellPoint, Inc. (NYSE: ... industry, today commended articles on diagnostic imaging that appear in the August 27, ... , The article "Exposure to Low-Dose Ionizing Radiation from Medical ...
... to detect the disease while it is still treatable ... say they have found small molecules in the blood ... have diagnostic implications in the future. , Levels of ... from pancreatic cancer, the fourth-leading cancer killer in the ...
Cached Medicine News:Health News:San Francisco Mayor Gavin Newsom Talks About Immigration and Drugs on Azteca America's 'Issues: Caras y Voces' 2Health News:Sometimes Angioplasty Can Wait 2Health News:VA Honors Veterans Who Are Artists, Performers 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 3Health News:American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 2Health News:Blood Test May Spot Pancreatic Cancer Early 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: